Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of ixabepilone in treating patients who
have relapsed or refractory lymphoproliferative disorders.